Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-24S + IL-15
- Development stage
- Preclinical
- Lead developer
- Virginia Commonwealth University
- Modality
- Gene Therapies, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intratumoral
01
Overview
IL-24S + IL-15 is a novel recombinant chimeric fusion cytokine consisting of an engineered, highly secreted version of Interleukin-24 (IL-24S or Superkine) and Interleukin-15 (IL-15) connected by a flexible linker. Developed by researchers at Virginia Commonwealth University, this fusion protein is designed to provide a dual-action therapeutic effect against cancers such as glioblastoma. The IL-24S component induces cancer-specific apoptosis and toxic autophagy without affecting normal cells, while the IL-15 component promotes the activation, proliferation, and recruitment of natural killer (NK) cells and CD8+ T cells. In preclinical models, the fusion protein has been delivered via an adenoviral vector (Ad5) combined with focused ultrasound and microbubbles to penetrate the blood-brain barrier and target intracranial tumors.
- Other names
- IL-24S/IL-15 chimeric fusion cytokinerecombinant IL-24S/IL-15 fusion constructIL-24S/IL-15
02
Targets
IL2RG (Interleukin-2 receptor gamma subunit)IL15RA (Interleukin-15 receptor subunit alpha)IL2RB (IL-2 receptor beta chain)IL20RA (Interleukin-20 receptor subunit alpha)IL20RB (Interleukin-20 receptor subunit beta)IL22RA1 (Interleukin-22 receptor subunit alpha-1)
Beyond the preview
Go deeper on IL-24S + IL-15.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-24S + IL-15.